Skagen

Seagen is a global biotechnology company that specializes in the discovery, development, and commercialization of transformative cancer treatments. As a pioneer in antibody-drug conjugates (ADCs), the company has developed a robust portfolio of FDA-approved therapies, including Adcetris, Padcev, Tivdak, and Tukysa. Seagen's proprietary technology platform combines the targeting precision of monoclonal antibodies with the potency of cytotoxic agents to selectively eliminate cancer cells while sparing healthy tissue. In December 2023, the company was acquired by Pfizer for approximately $43 billion, significantly expanding Pfizer's oncology pipeline and commercial capabilities. Seagen continues to advance a diverse clinical pipeline targeting various solid tumors and hematologic malignancies.